Project Details
Short title | MEK115306, A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC |
---|---|
Status | Finished |
Effective start/end date | 21/06/12 → 31/12/21 |
Funding
- Uhb Nhs Trust